BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, March 29, 2024
See today's BioWorld Asia
Home
» Australia’s Mesoblast plans to evaluate its stem cell therapy in patients infected with COVID-19
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Australia’s Mesoblast plans to evaluate its stem cell therapy in patients infected with COVID-19
March 17, 2020
By
Tamra Sami
No Comments
PERTH, Australia – Mesoblast Ltd. plans to evaluate remestemcel-L in patients with acute respiratory distress syndrome caused by coronavirus (COVID-19) in the U.S., Australia, China and Europe.
BioWorld Asia
Clinical
Infection
Inflammatory
Respiratory
Cell therapy
Australia